Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 16/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15539094 | 0.81 | PDE10A (0.40) | KDM4EMEN1KMT2APDE10A | |
| SCHEMBL12798307 | 0.81 | KDM4E (0.47) | KDM4EMEN1KMT2APDE10A | |
| SCHEMBL23748001 | 0.78 | KDM4E (0.46) | KDM4EMEN1KMT2APDE10AAKT1 | |
| SCHEMBL16972443 | 0.78 | PDE10A (0.51) | PDE10A | |
| SCHEMBL16972535 | 0.77 | PDE10A (0.49) | PDE10A | |
| SCHEMBL16972436 | 0.77 | PDE10A (0.50) | PDE10A | |
| SCHEMBL21301565 | 0.77 | PDE10A (0.46) | KDM4EMEN1KMT2APDE10AAKT1 | |
| SCHEMBL16972524 | 0.77 | PDE10A (0.49) | KDM4EMEN1KMT2APDE10A | |
| SCHEMBL18597010 | 0.77 | PDE10A (0.46) | KDM4EMEN1KMT2APDE10A | |
| SCHEMBL17515540 | 0.75 | KDM4E (0.43) | KDM4EMEN1KMT2APDE10AAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3786167-A1 | DIARYL MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | Primegene (Beijing) Co., Ltd. (CN) | 2021-03-03 | — | — | EP | disclosed |
| EP-3233862-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-03 | — | — | EP | disclosed |
| US-20170247327-A1 | OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-08-31 | — | — | US | disclosed |
| US-20160046632-A1 | OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160024007-A1 | OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046632-A1 | OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE | QDPR, DPYD, DHPS | KDM4E 1304/4885MEN1 2271/4885KMT2A 3514/4885 |
| US-20170247327-A1 | OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE | CLN6, ALDH1A2, C1S | KDM4E 4528/4885MEN1 2772/4885KMT2A 4446/4885 |
| US-20160024007-A1 | OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE | CLN6, ALDH1A2, C1S | KDM4E 4528/4885MEN1 2772/4885KMT2A 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.